BLAZE jatk.

On erinomaista, että tutkijalähtöiset kehitysprojektit on saatu alulle. Näissä organisaatiot ovat akateemisia, voittoa tavoittelemattomia, etumaksuja tms. ei välitetä ja oikeudet lääkkeeseen jäävät Faronille.  

https://www.icr.ac.uk/about-us/icr-and-the-royal-marsden 

ICR:n partnerina toimii The Royal Marsden NHS Foundation Trust, mikä on maailman johtava syöpiin erikoistunut sairaalaketju.

 

"The Royal Marsden NHS Foundation Trust is a world-leading specialist cancer hospital. The Institute of Cancer Research works in close partnership with The Royal Marsden to take the results of our research rapidly into the clinic, with the aim of developing better treatments for cancer patients."

Sairaalaketju hoitaa 50'000 potilasta kaikkialta maailmasta vuosittain. Monet potilaista saavat räätälöityä, molekyylidiagnostiikkaan perustuvaa hoitoa. 

"The Royal Marsden treats 50,000 patients from across the UK and abroad every year. Many of these patients benefit from tailored treatment programmes accomplished through provision of molecular diagnostics – allowing doctors to determine which specific treatments will be of most benefit to a particular patient."

  

Yhteistyö on tehokasta, 21 keskusta, esim.:

The Drug Development Unit was opened in February 2005 as a joint unit of the ICR and The Royal Marsden. In 2011, at the Experimental Cancer Medicine Centre Network quinquennial review, the unit was given a rating of ‘outstanding’ for past work and future plans. 

The ICR Clinical Trials and Statistics Unit (ICR-CTSU) leads the design, conduct and analysis of phase II and III national and international cancer clinical trials. Our findings directly influence clinical practice within the NHS and worldwide. 

Centre for Molecular Pathology is a collaborative initiative between The Royal Marsden the ICR that aims to identify the molecular mechanisms that drive cancers and to target them with a new generation of treatments.

The Centre for Protein Degradation is a virtual centre coordinating all aspects of molecularly driven protein degradation, from concept to clinic, both within and beyond the ICR. 

Faronin MAINE TIEDEYHTEISÖISSÄ takaa huippuammattilaisten osallistumisen lääketestauksiin.